Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 70.67% is 13% below its 5-year average of 81.62%, near the low end of its 5-year range (53.51%–145.28%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.80% above its 12-month average of 68.09%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
70.67%
RETURN ON EQUITY (ROE) AVG TTM
68.09%
RETURN ON EQUITY (ROE) AVG 3Y
62.53%
RETURN ON EQUITY (ROE) AVG 5Y
81.62%
RETURN ON EQUITY (ROE) AVG 10Y
102.54%
RETURN ON EQUITY (ROE) AVG 15Y
74.25%
RETURN ON EQUITY (ROE) AVG 20Y
55.35%
CURRENT VS TTM AVG
+3.80%
CURRENT VS 3Y AVG
+13.03%
CURRENT VS 5Y AVG
-13.41%
CURRENT VS 10Y AVG
-31.08%
CURRENT VS 15Y AVG
-4.82%
CURRENT VS 20Y AVG
+27.69%
SECTOR MEDIAN · HEALTHCARE
13.25%
median of 83 covered companies
CURRENT VS SECTOR MEDIAN
+433.38%
vs the sector median at left
IDEXX Laboratories, Inc.
Market Cap
$41.04B
Return on Equity (ROE)
70.67%
TTM Avg
68.09%
3Y Avg
62.53%
5Y Avg
81.62%
Market Cap
$41.48B
Return on Equity (ROE)
19.56%
TTM Avg
20.59%
3Y Avg
21.51%
5Y Avg
20.54%
Market Cap
$42.67B
Return on Equity (ROE)
22.28%
TTM Avg
21.77%
3Y Avg
21.17%
5Y Avg
17.55%
Market Cap
$42.81B
Return on Equity (ROE)
9.10%
TTM Avg
-6.34%
3Y Avg
-12.86%
5Y Avg
-14.53%
Market Cap
$34.80B
Return on Equity (ROE)
59.67%
TTM Avg
-187.43%
3Y Avg
134.89%
5Y Avg
51.69%
Market Cap
$48.40B
Return on Equity (ROE)
6.65%
TTM Avg
7.05%
3Y Avg
11.93%
5Y Avg
15.09%
Market Cap
$49.35B
Return on Equity (ROE)
3.85%
TTM Avg
6.60%
3Y Avg
6.50%
5Y Avg
6.42%
Market Cap
$49.93B
Return on Equity (ROE)
9.46%
TTM Avg
26.07%
3Y Avg
24.86%
5Y Avg
23.86%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $41.04B | 70.67% | 68.09% | 62.53% | 81.62% |
| Agilent Technologies, Inc. (A)vs › | $41.48B | 19.56% | 20.59% | 21.51% | 20.54% |
| IQVIA Holdings Inc. (IQV)vs › | $42.67B | 22.28% | 21.77% | 21.17% | 17.55% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.81B | 9.10% | -6.34% | -12.86% | -14.53% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.80B | 59.67% | -187.43% | 134.89% | 51.69% |
| Alcon Inc. (ALC)vs › | $33.71B | 2.96% | 4.58% | 3.90% | 2.45% |
| Humana Inc. (HUM)vs › | $48.40B | 6.65% | 7.05% | 11.93% | 15.09% |
| Becton, Dickinson and Company (BDX)vs › | $49.35B | 3.85% | 6.60% | 6.50% | 6.42% |
| Edwards Lifesciences Corporation (EW)vs › | $49.93B | 9.46% | 26.07% | 24.86% | 23.86% |
| ResMed Inc. (RMD)vs › | $32.06B | 23.13% | 23.30% | 22.33% | 21.49% |
ROE
70.7%
ROA
33.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 70.67% |
| 2026-03-31 | 70.38% |
| 2025-12-31 | 65.99% |
| 2025-09-30 | 65.81% |
| 2025-06-30 | 67.56% |
| 2025-03-31 | 61.81% |
| 2024-12-31 | 55.65% |
| 2024-09-30 | 53.54% |
| 2024-06-30 | 53.51% |
| 2024-03-31 | 55.23% |
| 2023-12-31 | 56.92% |
| 2023-09-30 | 63.41% |
| 2023-06-30 | 72.35% |
| 2023-03-31 | 83.13% |
| 2022-12-31 | 111.56% |
| 2022-09-30 | 140.68% |
| 2022-06-30 | 145.28% |
| 2022-03-31 | 114.81% |
| 2021-12-31 | 107.95% |
| 2021-09-30 | 100.28% |
| 2021-06-30 | 97.38% |
| 2021-03-31 | 95.95% |
| 2020-12-31 | 92.04% |
| 2020-09-30 | 112.92% |
| 2020-06-30 | 168.56% |
| 2020-03-31 | 405.73% |
| 2019-12-31 | 241.01% |
| 2019-09-30 | 208.91% |
| 2019-06-30 | 237.83% |
| 2019-03-31 | 756.88% |
| 2016-09-30 | 390.20% |
| 2015-03-31 | 534.70% |
| 2014-12-31 | 154.79% |
| 2014-09-30 | 86.84% |
| 2014-06-30 | 42.56% |
| 2014-03-31 | 37.00% |
| 2013-12-31 | 36.24% |
| 2013-09-30 | 35.13% |
| 2013-06-30 | 33.68% |
| 2013-03-31 | 28.89% |
| 2012-12-31 | 28.02% |
| 2012-09-30 | 28.00% |
| 2012-06-30 | 28.58% |
| 2012-03-31 | 29.27% |
| 2011-12-31 | 29.98% |
| 2011-09-30 | 27.33% |
| 2011-06-30 | 25.68% |
| 2011-03-31 | 24.27% |
| 2010-12-31 | 24.60% |
| 2010-09-30 | 24.86% |
| 2010-06-30 | 25.31% |
| 2010-03-31 | 25.99% |
| 2009-12-31 | 23.75% |
| 2009-09-30 | 22.98% |
| 2009-06-30 | 23.16% |
| 2009-03-31 | 25.72% |
| 2008-12-31 | 26.51% |
| 2008-09-30 | 27.01% |
| 2008-06-30 | 27.60% |
| 2008-03-31 | 23.18% |
| 2007-12-31 | 21.45% |
| 2007-09-30 | 22.17% |
| 2007-06-30 | 24.01% |
| 2007-03-31 | 23.40% |
| 2006-12-31 | 22.86% |
| 2006-09-30 | 22.97% |
| 2006-06-30 | 23.72% |
| 2006-03-31 | 21.71% |
| 2005-12-31 | 21.21% |
| 2005-09-30 | 19.74% |
| 2005-06-30 | 18.93% |
| 2005-03-31 | 20.19% |
| 2004-12-31 | 19.70% |
| 2004-09-30 | 18.05% |
| 2004-06-30 | 16.52% |
| 2004-03-31 | 14.71% |
| 2003-12-31 | 13.81% |
| 2003-09-30 | 14.27% |
| 2003-06-30 | 14.51% |
